FDA BIOEQUIVALENCE REQUIREMENTS FOR GENERIC DIAZEPAM SHOULD INCLUDE SITE-OF-ACTION PHARMACODYNAMIC STUDIES, ROCHE TELLS FDA; VALIUM OFF PATENT